Clinical trials: Non-Small Cell Lung
Non-Squamous Non-Small Cell Lung Cancer
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) GDC-0941 administered with one of three planned regimens: Arm A: paclitaxel and carboplatin…
- Trial name
- NCT00974584
- Testing
- GDC-0941, bevacizumab, carboplatin
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 65 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.
Advanced Cancer
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with…
- Trial name
- NCT03674567
- Testing
- FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
- Where
- 35 sites in United States, Australia and 4 more
- Volunteers
- 323 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Carcinoma, Non-Small-Cell Lung
Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer
Feasibility of pragmatic concomitant chemo-radiotherapy association with 1 cycle of Induction chemotherapy, weekly chemo-radiotherapy, and consolidation chemotherapy.
- Trial name
- BIB 01 (NCT00210171)
- Testing
- Toxicity : Time to progression, 1 and 2 years survival
- Where
- 7 sites in France
- Sponsor
- Institut Bergonié
NSCLC, Stage I
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)
This is a randomized multicentre open label phase II study of Durvalumab following Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC.
- Trial name
- ASTEROID (NCT03446547)
- Testing
- Durvalumab
- Where
- 15 sites in Finland, Norway and 1 more
- Volunteers
- 106 people
- Sponsor
- Vastra Gotaland Region
PD-L1 Positive Non-small Cell Lung Cancer
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.
- Trial name
- NCT04203485
- Testing
- Camrelizumab 200mg, Apatinib Mesylate 250mg, Pemetrexed disodium for injection
- Volunteers
- 762 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Lung Cancer Non Small Cell
A Study of Lymph Node Metastatic Pattern Based Incorporating Tumor Location, GGO Components and Size for Non-small Cell Lung Cancer
The goal of this observational study is to learn about in invasive non-small cell lung cancer patients who underwent pulmonary resection with systematic lymph node dissection from April 2008 to July 2022 .
- Trial name
- NCT06161935
- Testing
- no intervention
- Volunteers
- 7,067 people
- Sponsor
- Fudan University
Non-Squamous Non-Small Cell Neoplasm of Lung
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC
This is a randomized, multicenter, double-blind placebo-controlled phase 3 study of efficacy and safety of BCD-100 in combination with pemetrexed+cisplatin/carboplatin compared to placebo in combination with…
- Trial name
- DOMAJOR (NCT03912389)
- Testing
- BCD-100, Pemetrexed, Cisplatin (or carboplatin)
- Where
- 37 sites in Czechia, Georgia and 4 more
- Volunteers
- 292 people
- Sponsor
- Biocad
Malignant Pleural Effusion, Nonsmall Cell Lung Cancer, Stage IV
A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC
This randomized phase II study compare survival outcomes and toxicity of malignant pleural effusion stage IV non small-cell lung cancer patients Intrapleural infusion chemotherapy in combination with concurrent thoracic radiation…
- Trial name
- NCT03987087
- Testing
- Radiation, Chemotherapy
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Guizhou Medical University
Carcinoma, Non-Small-Cell Lung, EGFR Gene Mutation
In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing
The PRECISE-EGFR study is a prospective, observational project designed to generate patient-derived in vitro models (cell cultures and organoids) from individuals with non-small cell lung cancer (NSCLC) carrying EGFR mutations.
- Trial name
- PRECISE-EGFR (NCT07697716)
- Volunteers
- 30 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Carcinoma, Non-Small-Cell Lung
Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma
Cares for elderly patients with advanced non-small cell lung cancer(NSCLC) become one of the common clinical practices oncologist are now facing. So, we need to seek adequate regimens for them.
- Trial name
- NCT00625352
- Testing
- Gemcitabine, UFT
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Ulsan University Hospital
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
This randomized phase II trial is studying carboplatin, paclitaxel, and vorinostat to see how well they work compared with carboplatin, paclitaxel, and a placebo in treating patients with stage III or stage IV non-small cell lung…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00481078
- Testing
- vorinostat, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
An Open, Randomized, Multicentre, Phase II Pilot Study
The objective of this study is to evaluate efficacy, safety and quality of life adjuvant docetaxel-cisplatin chemotherapy versus no adjuvant treatment in patients with completely resected NSCLC Stage I-II.
- Trial name
- NCT00293085
- Testing
- Docetaxel
- Volunteers
- 37 people
- Sponsor
- Central European Cooperative Oncology Group
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)
This randomized parallel group study will assess the efficacy and safety of erlotinib [Tarceva], as monotherapy or intermittent dosing with docetaxel, in second-line setting in former-smoker male patients with advanced or…
- Trial name
- NCT01204697
- Testing
- docetaxel, erlotinib [Tarceva]
- Where
- 20 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer, Advanced Solid Tumor
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Hematologic Malignancy
- Trial name
- NCT06484816
- Testing
- TGRX-1942
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
NSCLC
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
Patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with brain metastases remain a major clinical challenge.
- Trial name
- NCT07413952
- Testing
- Limertinib Plus Radiotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Advanced Non-small Cell Lung Cancer, EGFR Mutation
A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor…
- Conditions
- Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
- Trial name
- NCT06378658
- Testing
- BAY2927088, Esomeprazole, Food
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Bayer
Non-Small Cell Lung Cancer
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety and preliminary efficacy of sorafenib following chemoradiation in locally advanced NSCLC.
- Trial name
- NCT00417248
- Testing
- Cisplatin, Etoposide, Radiotherapy
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- Nasser Hanna, M.D.
Non Small Cell Lung Cancer
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
This is a pilot single institution study of DRibble vaccination + GM-CSF in patients with stage IIIB or IV NSCLC who have undergone 0-1 chemotherapy regimens for metastatic disease.
- Trial name
- DRibble (NCT00850785)
- Testing
- DRibble vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
NSCLC, Stage I, NSCLC, Stage II
The Role of Microbiota on the Development of Lung Cancer
Relationship between human microbiota and epidemiology of lung cancer
- Conditions
- NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III, NSCLC Stage IV
- Trial name
- NCT03454685
- Testing
- without intervention type
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xiaorong Dong
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.